Member Info for PM2022

Blah, Blah, Blah. The time to add is now. I think this will be a 5-10 bag this year. Enough cash until middle of 2024 plus 201 deal to get done this year and very soon and more revenue contracts to come therefore we are just fine.

Public info for 201 to get done this year and I think Adam knows this which is why BOD all got elected again. Plus he has seen the lab plans and feels it will be very successful and will attract large ii.

It basically takes nothing much at all to double the SP from here. 6 million market cap.

301 news due. Move to SPV a possibility

lab contracts. SIgnificant revenue

201 deal based on presentations the deal is expected to be completed this year. That is still the case. Believe it or not but if it happens then what.

CLX update/deal

New evaluations

6p to 66p is a ten bagger. 201 gets done and we hopefully open up 300/400%. Then new evaluations in pipeline, lab contracts and ii buying in and we go past that level. Val will rise again those buying here will do well I am sure. Not much left to get right from 6 million.

I have taken this from the Turner Pope broker note just to point out to everyone including Stock01. Note the term HIGH MARGIN. Suggests very significant revenue coming in the coming months. Our cash burn is very low and we should get lots of news on the drug development side. This is the reason why I feel we are at the bottom and should multibag from here.

ValiRx’s management see potential for

this to develop into a ‘substantial working relationship’ between the two

companies, while also raising an important marketing banner for Inaphaea’s

broader offering. Given that it has already identified an extended list of other

potential customers, ValiRx is confident Inaphaea will secure further service

contracts capable of generating high margin revenues in the coming months.

It's not a ramp because the company is worth far more . 201 is still in play believe it or not so whilst due to market conditions and 201 delays it may have gone down the reverse will also apply imo. CLX at this stage costs more to develop than our mc and can get much more in upfront payments due to potential. Was 10/20 million upfront suggested by some as a minimum at this moment of time.

Even without 201 and based on some expert opinions we should not really be below 25-30p. With 201 the sky is the limit.

Judging from your posting history you were saying the opposite thing for 4D and look what happened.

Ramping day and night buying from 90p down to 16p before it went bust.

Valirx has cash until well into 2024.

Confirmation of more revenue contracts due this year as highlighted in TP report, CLX updates (more than one) and new compounds to come in. 201 is also still on for this year.

Easy multibagger from here given the amount of news due. Now generating revenue, warrants will give more cash so maybe with some luck then no placing ever if the CLX deal comes before the end of 2024.

Yes RB. Worth a read.

From the TP note the cash runway is for 12 months covering overheads.

More contract wins in H2 2023 so fairly soon.

Cytolytic progress updates in the next 12 months. So more than 1.

201 is still ongoing. I understand that it is still on to complete this year as well.

Lots of chances to multibag here.

We should comfortably multibag over the coming weeks/months from such a low price.

No because almost every AIM biotec has many more shares in issue. Look at RedX= 335 million, HEMO = 1100 million and many others VAL only has 100 million.

Another one is still easily 100-200p possible with a CLX deal in the future and if and when the market improves plus 201.

Just needs a few buyers here so I would think this is the bottom with lots more news to come.

Https://twitter.com/adshargreaves/status/1681570585921372160?s=46&t=xdsQNV0n_ZHRmadh3y3aIA

We will get many decent contracts over the coming months. Adam is also helping them plus they have all the old Imogen clients.

The real big news to come this year:

1) More compounds coming in.

2) 201 deal is on for this year

3)301 in our lab in our control so I'm expecting news very soon. A move into SPV is likely.

4) CLX update/ deal in the next 6-12 months.

Any of those things happen we should move up fairly quickly. Decent upside from here at a great price to just buy and hold.

Key point revenue will attract the big investors and with only 100 million shares even without news we will eventually move to a really decent price.

Only a 3 month project so imagine you get a few of these by next year which will happen. I can see updates coming for 301 and CLX this year as it will worked on quickly in our lab.

It doesn't need much to double from here from 7p.

It should be a decent amount as they will get further payments later on as well subject to milestones.

More will come lots more so this should significantly reduce the cash burn rate which is already low.

Update on CLX at some point in the next 6 months could multibag us from this buy. Don't forget 201 is still also on for this year.

No placing needed until middle of 2024 and not before lots of news. 6p just needs a few buys to take this to 10p and above. 201 is still on for this year and if it comes we will likely be open at a new price maybe 30p.

Note the likes of other AIM biotechs who have far more shares than VAL and probably have less potential.

HEMO 1,1042 MIllion shares. That is equivalent to about 24 dilutions at 5p for £2.5 million each time. They have been to 4p this year. Val only has 100 million shares. That would last VAL 24 years at the current burn rate. I would argue VAL has more than they do right now. Therefore whatever happens VAL should significantly multibag from here.

They only have an authorization of 20 million shares for cash. 120 million is nothing the SP would still go to 30/40/50/100p with a decent deal or 201 etc or smaller news.

More likely is that 201 gets done and we hit 25/30p in this market with some lab contracts. Only those in will benefit the most the market cap being so low it should open up 200/300% up.

Either way a win-win in my opinion to buy at this price. Likely you will get 100/200% before any placing imo. DYOR.

I mean 7p is a buy. News should be coming soon. This will move fast when it comes. Possible lock out.

Tough luck but I am based on facts as stated in Cenkos report unlike you plus revenue to come in plus 201 plus warrants if that happens giving more cash.

6p is a buy with lots of news to come. Easy 100/200 per cent before any hint of placing imo. Down to people to decide but they will not need to or want to place at 5p and they have time. 10p maybe or much higher with 201 but not here.

Public information was that 201 will get done this year for those that watched the presentations. My view is that they reassured Adam based on information already given to us. Hence they won the votes. Also they would have spoken about the lab and I guess he must have felt confident of making this a success. Unlike Pokry he understands the potential.

Therefore those buying at 6p are likely to see at least 10 bagger fairly easily. With good news the opportunity will be missed. Val does not burn much cash so a great buy.

The lab and decent revenue will attract huge investors and with say 110-120 million shares by then VAL will easily hit 100p even with a small deal imo.

No placing needed until middle of 2024 and not before lots of news. 6p just needs a few buys to take this to 10p and above. 201 is still on for this year and if it comes we will likely be open at a new price maybe 30p.

Note the likes of other AIM biotechs who have far more shares than VAL and probably have less potential.

HEMO 1,1042 MIllion shares. That is equivalent to about 24 dilutions at 5p for £2.5 million each time. They have been to 4p this year. Val only has 100 million shares. That would last VAL 24 years at the current burn rate. I would argue VAL has more than they do right now. Therefore whatever happens VAL should significantly multibag from here.

They only have an authorization of 20 million shares for cash. 120 million is nothing the SP would still go to 30/40/50/100p with a decent deal or 201 etc or smaller news.

More likely is that 201 gets done and we hit 25/30p in this market with some lab contracts. Only those in will benefit the most the market cap being so low it should open up 200/300% up.

Either way a win-win in my opinion to buy at this price. Likely you will get 100/200% before any placing imo. DYOR.

No placing needed until middle of 2024 and not before lots of news. 6p just needs a few buys to take this to 10p and above. 201 is still on for this year and if it comes we will likely be open at a new price maybe 30p.

Note the likes of other AIM biotechs who have far more shares than VAL and probably have less potential.

HEMO 1,1042 MIllion shares. That is equivalent to about 24 dilutions at 5p for £2.5 million each time. They have been to 4p this year. Val only has 100 million shares. That would last VAL 24 years at the current burn rate. I would argue VAL has more than they do right now. Therefore whatever happens VAL should significantly multibag from here.

They only have an authorization of 20 million shares for cash. 120 million is nothing the SP would still go to 30/40/50/100p with a decent deal or 201 etc or smaller news.

More likely is that 201 gets done and we hit 25/30p in this market with some lab contracts. Only those in will benefit the most the market cap being so low it should open up 200/300% up.

Either way a win-win in my opinion to buy at this price. Likely you will get 100/200% before any placing imo. DYOR.

Nomlungo,

Val has done 1000% a few times before. If 201 gets done it will be the first deal for the company. Previously it went up with just results and anticipation not actual completed deal. It went from 3p to 74p and 20p to 64p before and previously 1000% from 1 p to 10p.

Now we have CLX, revenue to come, assets and new compounds to come. The company has more than it has ever had. I think we should be 30p already without 201 so if it gets done sentiment will change. I would expect the company to open at a new price.

I stated 100-1000% comfortably if 201 completes within 12 months from now but more likely 500-1000% is fair. I am sure most would agree and it is not unreasonable. Not ramping but facts and opinions.

I am not ramping, your deramping, I am only stating facts which are we are undervalued at 6 million and we have plenty of news due. Adam stated he felt CLX alone was worth 20 p so I am not sure who you are to say that is wrong. Furthermore, you will say it is worth what someone pays but the facts remain they can sell it at any stage. At that point the SP will open up multiples of where we are.

Suzy confirmed that the situation with 201 is as previously stated in previous presentations although not guaranteed.

You're desperate Porky but I think you will miss out.

Is that why you spend all your time on this board doing nothing else.

I see this as an escape from all your 4D losses. Almost everything is priced at zero and it should be fairly easy for the BOD to deliver from this level.

Anyone buying here could well see a 1000% rise if 201 comes good as expected with some other news added and revenue coming through.

I have a glance it does not mean I read it. I can see he pretends to not agree with my figures.